Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's total liabilities are $30.79 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2023-12-31 | $30.79 B | 35.54% |
2022-12-31 | $22.72 B | 20.58% |
2021-12-31 | $18.84 B | 39.7% |
2020-12-31 | $13.48 B | 32.26% |
2019-12-31 | $10.19 B | 12.95% |
2018-12-31 | $9.02 B | 6.6% |
2017-12-31 | $8.47 B | 14.45% |
2016-12-31 | $7.40 B | 12.65% |
2015-12-31 | $6.56 B | 9.4% |
2014-12-31 | $6.00 B | 16.81% |
2013-12-31 | $5.14 B | 15.8% |
2012-12-31 | $4.43 B | -6.48% |
2011-12-31 | $4.74 B | 8.85% |
2010-12-31 | $4.36 B | 19.1% |
2009-12-31 | $3.66 B | 10.36% |
2008-12-31 | $3.31 B | 8.87% |
2007-12-31 | $3.04 B | 17.98% |
2006-12-31 | $2.58 B | 14.05% |
2005-12-31 | $2.26 B | 13.01% |
2004-12-31 | $2.00 B | 28.87% |
2003-12-31 | $1.55 B | 27.22% |
2002-12-31 | $1.22 B | -2.17% |
2001-12-31 | $1.24 B |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $137.21 B | 345.58% | ๐บ๐ธ USA |
Eli Lilly LLY | $53.14 B | 72.57% | ๐บ๐ธ USA |
Sanofi SNY | $57.61 B | 87.09% | ๐ซ๐ท France |
Bristol-Myers Squibb BMY | $65.67 B | 113.27% | ๐บ๐ธ USA |